Document M4zoMQB0VjD8GOK71Rng9BYRy
EXHIBIT 1
Table A. PFOA levels by water district/source.
PFOA Levels (ppb) 1.7-4.3
Location Little Hocking, Ohio
0.4-3.9
Lbeck, WV
0.25-0.37
Tuppers Plains, Ohio
0.08-0.13
Belpre, Ohio
0.06-0.1
Mason, WV
0.06-0.07
Pomeroy, Ohio
0.165
Blennerhassett
1.0-5.0
Dupont, W ashington Works
1.75-1.87
GE Plastic
0.05-8.6
68 Private W ells W VA & Ohio
Abbreviations: N'A Not Applicable
H o u s e h o ld s 4200 3700 4800 6000 4200 1000 71 N/A N/A 68
3
Table B. Demographics in a rcsidentially PFOA-exposed population.
Variable
Categories
n
Age
20 - 34
105
35 44
104
45 - 54
135
55 - 64
154
65 - 80
80
Percentage 18.17 17.99 23.36 26.64 13.84
Gender
Male Female
284 294
49.13 50.87
Race/Ethnicity
White African American
Others
558 6 9
97.38 1.05 1.57
Education
Less than 9lh grade 9 - 11th-grade
12"7Vocational/Some College
College Graduate
17 59 430
65
2.98 10.33 75.31
11.38
Body Mass Index (BMI)
Underweight (<23) Average (23 - 28) Overweight (>28 )
106 190 276
18.53 33.22 48.25
Smoking Habit
Never smoked Smoked less than 15
years
Smoked more than 15 years
252 72
92
Work History
Plant 1 Plant 2 No plant work
54 19 500
60.58 17.31
22.12
9.42 3.32 87.26
Table C. Unadjusted odds ratios o f cancer and 95% confidence interval for demographic variables o f a population residential ly
exposed to PFOA.
Variable
Categories
# Cancer Obs. Used Percentage Odds Ratio 95% Cl P-value
in Logistic
with Cancer
Regression
Gender Age
Education
Male Female **
20 - 34 ** 35 44 45 54 55 - 64 65 80
Less than 9th grade 9th grade or higher **
25 25
5 4 9 16 16
8 42
8.80% 8.50%
4.76% 3.88% 6.67% 10.39% 20.00%
47.06% 7.58%
1.04 (0.58 - 1.86) 0.9 1 --
0.0002* 1 -0.8 (0.21 - 3.07) 0.74 1.43 (0.46 4.40) 0.53 2.32 (0.82 6.54) 0.11 5 (1.75 14.32) 0.003
10.84 1
3.97-29.53 <0.0001 --
Body Mass Index (BMI)
Smoking Habit
Underweight (<23) Average (23 - 28) **
Overweight (>28 )
8 18 23
7.55% 9.47% 8.33%
0.93* 0.78 (0.33 - 1.86) 0.58
1 -0.87 (0.46 1.66) 0.67
0.16*
Jo
Never smoked ** Smoked less than 15 years
Smoked more than 15 years
20 7 12
7.94% 9.72% 13.04%
Work Site
Plant 1
8
Plant 2
1
No plant employment **
41
* p-value refers to the p-vaiue for a test for trend ** Denotes the reference value o f each variable for the logistic regression
14.81% 5.26% 8.20%
1 .. 1.25 (0.51 3.08) 0.63 1.74 (0.81 3.72) 0.15
1.87 (0.83 4.22) 0.13 0.48 (0.06 3.62) 0.47
1 --
fable D. Comparison of total cancer prevalence rates (per 100,000) between PFOA-exposed resident population and the US
population (Whites only) by age and gender.
US Population Exposed Population
Prevalence Ratio
Age Group 20-34 35-44 45-54 55-64
65+
Age Specific
Rates Male
338 799 1,722 5,080
15,661
Age Specific
Rates Female
451 1,447 3,167 5,390
9,173
Age Specific
Rates Male 1,923
-
4,839 9,211 32,558
Age Specific
Rates Female
7,547 7,547
8,219 11,538
5,405
Rates ratio of
Exposed/US
Rates ratio of
Exposed/US
Males P-value Females P-value
5.69
0.16
16.75
0.0001
- - 5.21 0.008
2.81 0.09 2.59 0.03
1.81 0.1 2.14 0.03
2.08 0.009 0.59
0.85
Table E. Standardized Morbidity Prevalence ratio comparing age-adjusted observed cancer rates (per 100,000) to expected cancer rates
CANCER TYPE
Number of Cases Observed Rates Age Adjusted Prevalence Confidence
(per 100,000) Expected Rates Ratio
Interval
(per 100,000)
All Cancer
50
8,651
3,426
2.58 1.91 -3 .4 7 *
Bladder
5 865 163 5.3 2.19 - 12.87*
Breast
5
1,701
1,579
1.12 0.46 2.71
Colon/Rectal
4
692 261 2.65 0.99 - 7.11
Kidney
1 173 79 2.2 0.31 - 15.63
Lung
7
1,211
153 7.89 3.72 - 16.74*
M. Myeloma
2
346 22 15.71 3.91 63.14*
Melanoma
3
519 214 2.42 0.78 - 7.54
Non-Hodgkins
5
865 130 6.67 2.76 - 16.13*
Prostate
9
3,169
1633 1.96 0.98 - 3.92
Uterine and/or Cervical
9
3,061
96 33.12 17.03 64.41*
* Excludes the null value
I'ablc F. Demogra allies in an occupationally PFOA-exposed population
Variables
Categories
n Percentage
Birth Year
1900 1919 1920 - 1939 1940-1959 1960 1989
160 1209 2203 682
3.76 28.42 51.79 16.03
Gender
Male Female
3583 671
84.23 15.77
Years of Occupational
Exposure
<21 years 21 29 30 50
1266 1462 1366
30.92 35.71 33.37
Working Condition
No direct PFOA exposure
Direct PFOA exposure
2157 1388
60.85 39.15
Table G. Age-adjusted Proportional Hazard ratios o f certain types o f cancers among workers hired between 1950 and 1990, between
those working in departments with direct PFOA exposure and those with no direct exposure.___________________
Cancer Type
Department Environment
Number of Percentage with Hazard Ratio
Cancer
Cancer
Cl
P-value
Incidents
Pancreatic Cancer No direct exposure Direct PFOA exposure
Respiratory Cancer
No direct exposure Direct PFOA exposure
Kidney Cancer
No direct exposure Direct PFOA exposure
Colon/Rectal Cancer
No direct exposure Direct PFOA exposure
Prostate Cancer
No direct exposure
Direct PFOA exposure
Non-Hodgkin's Lymph
No direct exposure Direct PFOA exposure
Bladder Cancer
No direct exposure
2 6
11 26
6 11
9 11
14 23
3 3
10
0.09% 0.48%
0.51% 2.10%
0.28% 0.89%
0.42% 0.89%
0.65% 1.86%
0.14% 0.24%
0.46%
1 4.46 (0.87,22.91) 0.07
1 4.41 (2.13,9.13) <0.0001
1 3.14 (1.10,8.95) 0.03
1 2.96 (1.15,7.64) 0.02
1 2.51 (1.24,5.08) 0.01
1 2.44 (0.47, 12.73) 0.29
1
y/
Direct PFOA exposure
Liver Cancer
No direct exposure Direct PFOA exposure
Breast Cancer
No direct exposure Direct PFOA exposure
10
1 1
5 1
0.81%
0.05% 0.08%
0.23% 0.08%
1.46 (0.59,3.54) 0.41
1 1.13 (0.06.23.07) 0.94
1 0.21 (0.02, 1.88) 0.16
Table H. Logistic regression analysis controlling for age and work environment
Cancer Type
Years of Exposure
Adjusted Odds Ratio
95% Cl
P-Value
Prostate
<21 years 21 - 29 30-50
0.0002*
1-
-
2.68 0 .8 2 -8 .7 9
0.1
8.71
2.63 -28.83
0.0004
Kidney
<21 years 21 - 2 9 30 50
1 6.28 11.57
0.75 - 52.89 1.38 -9 7 .3 2
0.03* -
0.09 0.02
Respiratory
<21 years 21 29 30 - 50
0.07*
1-
-
1.42 0.61 -3 .3 0
0.42
1.47 0.63 - 3.43
0.37
Bladder
<21 years 21 29 30 50
0.17*
1-
-
1.3 0.40 - 4.24 0.66
2.09 0.59 - 7.40 0.29
Colon/Rectal
0.24*
<21 years 21 29 30 - 50
10.38 0 .1 0 - 1.50 1.41 0.50 - 4.00
Pancreatic
<21 years
1
21 29
1.71
30-50
1.92
p-value refers to the p-value for a test for irent
0.28 10.49 0.28 - 13.20
0.17 0.52
0.35* -
0.56 0.51
/4
Table A. Standardized Prevalence Ratio (SPR) comparing observed disease rate per
100.000 among a rcsidentially PFOA-exposed population to the expected disease rate of
the general L.S. population controlling for age and gender.
D isease or Sym ptom Type
Num ber d is e a se d in exp osed
group
O bserved R ates
(per 100.000)
Expected R ates3 (per 100.000)
SPR
C Ib
Cardiovascular problems'
Chronic bronchitis Kidney disease
170 113
21
30,088 22,114 3,757
7,019 6,145 1,665
4.29 3 .4 7 - 5.29* 3.60 2.92 -4.44* 2.26 1.45-3.51*
Shortness of breath on stairs Asthma
Thyroid problems Diabetes
323 105 82 56
57,270 20,669 15,589 9,947
27,994 11,369 10,019 6.457
2.05 1.70 - 2.46* 1.82 1.47 - 2.25* 1.56 1.22 - 1.98* 1.54 1.16 - 2.05*
High blood
pressure
186 33,096
28,077
1.18 0.97 - 1.43
Liver problems
19
3,754
3,728
1.01 0.64 - 1.59
^Expected rates are from NHANES 2001 - 2002 using sampling weights to calculate an unbiased estimate
of national rates while adjusting for non-response, survey design and sampling technique while giving an
accurate estimate of sampling error.
bConfidence Interval
'Includes MI. Stroke. Angina ^Statistically significant (p<0.05)
EXHIBIT 2
Table B. Prevalence Ratios (PR) comparing observed disease rate per 100,000 among a residentially PFOA-exposed population to the expected disease rate of the general U.S. population by age group and gender for various disease outcomes.
Males
Females
Prevalence Ratio
Age Group
Age Specific
Rates (US8)
Age Specific
Rates (EPb)
Asthma 12543.8
18-34 7 35-49 7895.13 50-64 9363.58 65+ 5694.06
37209.30
14705.88 12903.23 19047.62
Chronic Bronchitis 18-34 4136.27 23255.81 35-49 4716.72 20000 50-64 2870.57 18750 65+ 5000.83 15000
High B ood Pressure 18-34 9799.81 22000
18366.5 21250 35-49 9
32115.1 37623.76 50-64 5
Age Specific
Rates (US)
15209.92
15149.32 13065.51 10790.07
5867.84 8192.81 8022.41 11843.53
7359.86 17218.61
38440.91
Age Specific Rates (EP)
30000
21052.63 21568.63 18181.82
18000 25333.33 27884.62 25000
9090.91 13414.63
50877.19
EP/US Males
P
2.97 <0.0001
1.86 0.0005 1.38 0.002 3.35 <0.0001
5.62 <0.0001 4.24 <0.0001 6.53 <0.0001 2.99 0.0006
2.24 <0.0001 1.16 0.002
1.17 <0.0001
EP/US females
P
1.97 <0.0001
1.39 0.0003 1.65 <0.0001 1.69 0.01
3.07 <0.0001 3.09 <0.0001 3.48 <0.0001 2.11 0.0008
1.24 0.05 0.78 0.10
1.32 <0.0001
Males
Females
Prevalence Ratio
Age Group
65+
Age Specific
Rates (USa) 48057.7 7
Age Specific
Rates (EPb) 59090.91
Age Specific
Rates (US) 60185.45
Short o 'breath climbing stairs
18-34
-- 45098.04
18804.0 44444.44
35-49 2
33173.6 51960.78 50-64 2
37010.2 54545.45
65 t- 5
--
32506.6 6 42327.8 0 49553.3 6
Cardiovascular pro demsc
18-34 647.54
21568.63
35-49 3273.62 28395.06
50-64 8524.01 41176.47
26458.91 40909.09
65+
746.23 1775.02 7616.51 18080.3 6
Liver 18-34 35-49 50-64 65+
424.68 6240.89 5221.11 3400.71
2325.58 28.98.55 5376.34 2439.02
1696.30 2642.29 3983.46 3026.29
Age Specific Rates (EP) 57142.86
58181.82 56790.12 73684.21 71428.57
21818.18 21951.22 32456.14 25714.29
6122.45 4000 3921.57
--
EP/US Males 1.23
P <0.0001
--
2.36
--
<0.0001
1.57 <0.0001
1.47 <0.0001
33.31 8.67 4.83 1.55
<0.0001 <0.0001 <0.0001 <0.0001
5.48 0.09 0.46 0.63 1.03 0.10 0.72 0.50
EP/US
females
P
0.95 0.006
-- 1.75
1.74
1.44
<0.0001
<0.0001
<0.0001
29.24 12.37 4.26 1.42
<0.0001 <0.0001 <0.0001 0.005
3.61 1.51 0.98
--
0.009 0.08 0.15
-
/7
Males
Females
Prevalence Ratio
Age Age
Age
Specific Specific Specific
Age Rates
Rates
Rates
Age Specific EP/US
EP/US
Group (USa)
(EPb)
(US)
Rates (EP)
Males
P females
P
Kidney Disease 18-34 342.84 35-49 965.12 50-64 1497.24 65+ 6177.16
2000.00 2500.00 6930.69 4545.45
-- 267.94 2369.68 4083.52
3636.36 1234.57 1785.71 11428.57
5.83 0.08 -- --
2.59 0.06 4.61 0.10
4.63 <0.0001 0.75
0.38
0.74 0.39 2.80 0.006
Thyroid Disease
18-34
--
- 5761.79 13725.49
--
-- 2.38
0.0008
3551.87 35-49
5555.56
10420.1 20512.82 9
1.56 0.04
1.97 <0.0001
4169.26 7216.49 18424.4 30188.68
1.73 0.005 1.64
<0.0001
50-64
3
12164.48 11904.76 28167.6 32352.94 65+ 6
0.98 0.11
1.15 0.01
Expected rates are from NHANES 2001 - 2002 using sampling weights to calculate an unbiased estimate o f national rates while
adjusting for non-response, survey design and sampling technique while giving an accurate estimate of sampling error.
hPFOA-exposed population (EP)
Ml, Stroke, Angina
